Related Experiment Video
Updated: Apr 29, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.5K
Linagliptin: from bench to bedside
1Iatriko Palaiou Falirou Medical Center, Division of Diabetes, Athens, Greece.
Drug Design, Development and Therapy
|May 23, 2014
Summary
Linagliptin, a dipeptidyl peptidase-4 inhibitor, shows efficacy in lowering blood sugar and offers potential benefits beyond diabetes management. Preclinical and clinical studies reveal a favorable safety profile and unique pharmacokinetic properties.
Area of Science:
- Pharmacology and Therapeutics
- Endocrinology
- Cardiovascular Research
Background:
- Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of drugs used for type 2 diabetes.
- Linagliptin is a DPP-4 inhibitor with a unique pharmacokinetic profile.
- Comprehensive understanding of linagliptin's effects requires integrating preclinical and clinical data.
Purpose of the Study:
- To provide a comprehensive overview of linagliptin's physiologic effects.
- To summarize outcomes from both preclinical and clinical research on linagliptin.
- To explore potential applications of linagliptin beyond glycemic control.
Main Methods:
- Review of existing preclinical research on linagliptin.
- Analysis of clinical trial data for linagliptin.
- Synthesis of findings to present a holistic view of linagliptin's effects.
Main Results:
- Clinical studies show a favorable safety profile, weight neutrality, and significant glycosylated hemoglobin reduction (0.6-0.8%).
- Preclinical research indicates improved wound healing, reduced hepatic fat, decreased infarct size, and enhanced vascular function.
- Linagliptin does not require dose adjustment in renal dysfunction and reduces albuminuria.
Conclusions:
- Linagliptin demonstrates efficacy in glycemic control and possesses unique properties, including nonrenal clearance.
- Preclinical findings suggest potential therapeutic roles in wound healing, cardiovascular protection, and metabolic health.
- Further translational research is warranted to explore expanded applications of linagliptin and other incretin-based therapies.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
991
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
991
01:25Insulin: Biosynthesis, Chemistry, and Preparation
2.0K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.0K
01:27Insulin Formulations: Types and Delivery
1.2K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
1.2K